June 22 (Reuters) – AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline.
AbbVie has offered $135.11 per Apogee share held, which implies a 49.49% premium to Thursday’s close. Shares of Apogee were at $136.3 in premarket trading.
The deal gives AbbVie access to Apogee’s lead drug candidate, zumilokibart, an experimental treatment targeting a range of inflammatory diseases, including moderate-to-severe atopic dermatitis and asthma.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sriraj Kalluvila)
See More: https://www.ubirataonline.com.br
